Sponsored Supplement

Cost-Effective Treatment Option for von Willebrand Disease

Publish date: April 1, 2019
This supplement was neither developed nor peer reviewed by Journal of Clinical Outcomes Management. It is supported by Octapharma USA Inc.

 

Click here to read the supplement.

What can be done to provide a cost-effective treatment option for von Willebrand Disease?

Topics include:

  • Review of Key Clinical Studies and Surgical Procedures
  • Pharmacokinetics Comparison
  • Pharmacoeconomic Comparisons

Click here to read the supplement.

Recommended Reading

Opioids appear safe for sickle cell pain
Journal of Clinical Outcomes Management
Gut bacteria influence HCT outcomes
Journal of Clinical Outcomes Management
2018: A banner year for hematology drug approvals
Journal of Clinical Outcomes Management
NCI director: Data failures cost lives
Journal of Clinical Outcomes Management
Phase 3 data support apixaban for cancer-associated VTE
Journal of Clinical Outcomes Management
Poor-prognosis cancers linked to highest suicide risk in first year
Journal of Clinical Outcomes Management
Sickle cell infusion gains FDA breakthrough designation
Journal of Clinical Outcomes Management
Biomarkers predict VTE risk with menopausal oral hormone therapy
Journal of Clinical Outcomes Management
Barriers to CAR T use in the spotlight at first European meeting
Journal of Clinical Outcomes Management
Myeloma therapies raise cardiovascular risks
Journal of Clinical Outcomes Management